Cargando…
REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
INTRO: On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19 symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment with Paxlovid (Ritonavir-Boosted Nirmatrevir). We describe two patients who experienced a rebound of COVID-19 after recei...
Autores principales: | Periyasamy, P., Fen, T. Li, Kori, N., Zainulabid, U.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186955/ http://dx.doi.org/10.1016/j.ijid.2023.04.318 |
Ejemplares similares
-
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
por: Wang, Lindsey, et al.
Publicado: (2022) -
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
por: Alshanqeeti, Shatha, et al.
Publicado: (2022) -
An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023) -
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022) -
Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid
por: Wang, Yu, et al.
Publicado: (2022)